Sertraline effectiveness and safety in depressed oncological patients
- First Online:
- 224 Downloads
Goals of work
Cancer is often burdened by psychological comorbidity, mainly represented by depression, anxiety and adjustment disorders. Efficacy and tolerability of sertraline in the treatment of depressive disorders is well known; however, its efficacy and safety in patients with cancer has been poorly studied. This study was aimed to provide evidences of effectiveness, safety, tolerability and rapidity of action of sertraline in a population of oncological outpatients affected by mood disorders and its effects on quality of life.
Materials and methods
Thirty-five adult cancer outpatients with mood depression, during chemotherapy, were enrolled to a 12-week trial with a flexible dose regime of sertraline. The treatment response was assessed at baseline, week 4 and week 12, with hospital anxiety and depression scale (HADS) and Montgomery Asberg depression rating scale (MADRS), to rate depression and anxiety; mini mental adjustment to cancer scale (Mini-MAC), to assess the psychological response to the diagnosis of cancer; clinical global impression (CGI) to evaluate severity of illness; dosage record and treatment emergent symptom scale (DOTES), to assess the adverse effects of the clinical treatments and their possible relation with the drug used; and QL index to rate quality of life.
Both mean depression scores, analysed by HADS and MADRS scales, and HADS anxiety scores significantly decreased during the 12 weeks of study. Mean MINI-MAC scores show that hopelessness and anxious preoccupation decreased significantly at T2 compared with T0. No severe adverse effects were observed.
In this preliminary study, sertraline was found to be effective and well tolerated in the treatment of depressed outpatients with cancer.
KeywordsSertraline Depression Cancer Psychoncology
- 1.American Psychiatry Association (2000) DSM-IV-TR: diagnostic and statistical manual of mental disorders, text revision, 4th edn. American Psychiatry Association, Washington, DCGoogle Scholar
- 3.Binaschi L, Berra C, Caldera P, Torta R, Mussa A (2006) Somatic, affective and cognitive symptoms for diagnosing mood disorders in cancer patients. Psychooncology 15(S2):176–177Google Scholar
- 6.Evans DL, McCartney CF, Haggerty JJ Jr, Nemeroff CB, Golden RN, Simon JB, Quade D, Holmes V, Droba M, Mason GA et al (1988) Treatment of depression in cancer patients is associated with better life adaptation: a pilot study. Psychosom Med 50(1):73–76Google Scholar
- 7.Faller H, Bulzebruck H, Schilling S, Drings P, Lang H (1997) Do psychological factors modify survival of cancer patients? II: results of an empirical study with bronchial carcinoma patients. Qual Life Res 6(2):159–168 (Mar)Google Scholar
- 12.Grassi L, Biancosino B, Marmai L, Righi R (2004) Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry 65:4Google Scholar
- 14.Grassi L, Mangelli L, Fava GA, Grandi S, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N (2007) Psychosomatic characterization of adjustment disorders in the medical setting: some suggestions for DSM-V. J Affect Disord 101(1–3):251–254Google Scholar
- 15.Guy W (1976) ECDEU assessment manual for psychopharmacology, revised. US National Institute of Health, Psychopharmacology Research Branch, Rockville, MD, pp 223–244Google Scholar
- 21.Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PLR, Flynn PJ, Hynes HE, Banerjee TK, Kirshner JJ, King DK (2003) Differential effects of paroxetine on fatigue and depression: a randomized double-blind trial from the University of Rochester Cancer Centre Community Clinical Oncology Program. J Clin Oncol 21:4635–4641PubMedCrossRefGoogle Scholar
- 28.Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M, Desclaux B, Saltel P, Piollet I, Gauvain-Piquard A, Trichard C, Cordier B, Fresco R, Guillibert E, Sechter D, Orth JP, Bouhassira M, Mesters P, Blin P (1996) The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 94:205–210PubMedCrossRefGoogle Scholar
- 33.Somerset W, Stout SC, Miller AH, Musselman D (2004) Breast cancer and depression. Oncology (Williston Park) 18(8):1021–1034Google Scholar
- 35.Torta R, Mussa A (eds) (1997) Psiconcologia. Basi biologiche, aspetti clinici ed approcci terapeutici. Centro Scientifico Editore, TorinoGoogle Scholar
- 36.Torta R, Amodeo L, Berra C, Borio R, Caldera P, Scalabrino A (2003) Lo spettro di impiego degli psicofarmaci in oncologia. Ital J Psychopathol 9 SupplGoogle Scholar
- 37.Torta R (2006) Depression as a systemic disease: the antidepressants spectrum of action. Psychooncology 15(S2):2–3Google Scholar
- 39.Watson M, Law M, dos Santos M (1992) Coping with cancer: the Mini-MAC. ICPO, BeauneGoogle Scholar
- 40.World Medical Association (2002) Declaration of Helsinki: ethical principles for medical research involving human subject. 52nd WMA General Assembly. Edinburgh, Scotland (October)Google Scholar
- 41.Wu W, Yamaura T, Murakami K, Murata J, Matsumoto K, Watanabe H, Saiki I (2000) Social isolation stress enhanced liver metastasis of murine colon 26-L5 carcinoma cells by suppressing immune responses in mice. Life Sci 66(19):1827–1838Google Scholar
- 42.Wu W, Murata J, Hayashi K, Yamaura T, Mitani N, Saiki I (2001) Social isolation stress impairs the resistance of mice to experimental liver metastasis of murine colon 26-L5 carcinoma cells. Biol Pharm Bull 24(7):772–776Google Scholar